FDA cleared Acute market opportunity exists with EndeavorOTC, the first FDA-cleared digital treatment for adults with ADHD delivered via a video game. This could open doors for payer discussions, OTC channels, and expansion into broader neurology and psychiatry digital therapeutics partnerships.

Pipeline potential Akili is advancing a broad pipeline across neurology and psychiatry including ADHD, MDD, ASD, and inflammatory diseases, signaling multiple collaboration and licensing opportunities with pharma, biotech, and contract research organizations seeking digital therapeutic integrations.

Digital medicine The company blends neuroscience with engaging game development to deliver medicine digitally. This unique modality positions Akili for strategic alliances with gaming studios, digital health platforms, and healthcare providers looking to enhance patient engagement and adherence.

Financial scale With estimated revenue in the mid range of 25 to 50 million and a 51-200 employee base, Akili presents a scalable partner profile for integrative projects, joint ventures, or strategic equity discussions with larger pharma players seeking innovative digital solutions.

Commercial readiness Recent regulatory and investor activity indicates heightened visibility and potential acquisition or collaboration interest. This creates a favorable window for BD outreach centered on licensing deals, strategic partnerships, and accelerated go-to-market arrangements.